A follow up study [81] confirmed these results using genetic and pharmacologic inhibition of ERK activity, further exemplifying the notion that MEK/ERK signaling can antagonize the effect of JAK2 inhibitors, providing strong support for combining MEK or ERK inhibitors with JAK2 inhibitors in MPN (Fig. 1). This evidence concerns the gene MAP2K7 and myeloproliferative neoplasm.